Does SelectHealth Cover Vyvanse?

How SelectHealth Classifies Vyvanse on Its Formulary

SelectHealth, a nonprofit insurer operated by Intermountain Health, maintains a tiered formulary that groups medications by cost and clinical preference. Vyvanse (lisdexamfetamine) has historically appeared on Tier 3 or Tier 4 of SelectHealth's commercial formulary, meaning it carries higher cost-sharing than generic stimulants on Tier 1 or Tier 2.

The specific tier assignment varies by plan type. SelectHealth offers commercial employer-sponsored plans, individual marketplace (ACA) plans, Medicare Advantage (SelectHealth Advantage), and Medicaid managed-care products across its primary service areas in Utah and Idaho. Each product line publishes its own formulary, and tier placement for brand-name Vyvanse can differ between them. Commercial plans most often place it at Tier 3 with a copay ranging from $50 to $100, while Medicare Advantage plans may assign it to Tier 4 with coinsurance of 25% to 40% of the negotiated price 1.

Since generic lisdexamfetamine became available in August 2023, some SelectHealth formularies have added the generic version at a lower tier while shifting brand Vyvanse to a higher non-preferred tier or removing it from the formulary entirely. The FDA's approval of generic lisdexamfetamine opened the door for insurers to require generic substitution, a pattern SelectHealth has followed with other brand-to-generic transitions.

Members should verify their specific formulary placement by logging into the SelectHealth member portal or calling the number on the back of their insurance card. Formularies update at least annually, and mid-year changes do occur.

Prior Authorization and Step-Therapy Requirements

Most SelectHealth plans require prior authorization before covering Vyvanse. This is standard practice. The American Academy of Pediatrics (AAP) 2021 clinical practice guideline for ADHD recommends stimulant medications as first-line pharmacotherapy for children aged 6 and older, but does not specify brand over generic [2]. SelectHealth, like most insurers, uses this flexibility to require step therapy through less expensive agents first.

Step therapy typically means the prescribing clinician must document that the patient tried and either failed or experienced intolerable side effects with at least one generic stimulant. The most commonly required first-step agents include generic mixed amphetamine salts (the generic equivalent of Adderall), generic methylphenidate (the active ingredient in Ritalin and Concerta), and generic dextroamphetamine. Some plans require failure of two generic stimulants before approving Vyvanse.

The prior authorization form asks for diagnosis (ADHD or binge eating disorder), duration of current symptoms, previous medication trials with dates and reasons for discontinuation, and the prescriber's clinical rationale for choosing lisdexamfetamine specifically. According to a 2022 survey published in JAMA Network Open, prior authorization denials for ADHD medications affected roughly 20% of initial requests across commercial insurers, though most were overturned on appeal when adequate documentation was submitted 3.

SelectHealth processes most prior authorization requests within 72 hours for standard reviews and 24 hours for urgent requests. If denied, members have the right to appeal, and their prescriber can submit a formulary exception request citing medical necessity.

Why Vyvanse Costs More Than Other Stimulants

Vyvanse occupied a unique market position for over 15 years as the only available lisdexamfetamine formulation. Takeda Pharmaceuticals held patent protection until 2023, and brand-name Vyvanse carried a wholesale acquisition cost exceeding $400 per month. Even after generic entry, the brand version remains significantly more expensive than alternatives.

The pharmacokinetic profile of lisdexamfetamine partly explains its clinical niche. Lisdexamfetamine is a prodrug: it is pharmacologically inactive until enzymatic cleavage in red blood cells converts it to d-amphetamine 4. This conversion mechanism produces a smoother onset and a longer duration of action (approximately 10 to 14 hours) compared to immediate-release amphetamine formulations. A randomized controlled trial by Biederman et al. (N=290) demonstrated that lisdexamfetamine 30 mg, 50 mg, and 70 mg all showed statistically significant improvement in ADHD-RS-IV scores versus placebo (P<0.001 for all doses) 5.

The prodrug design also gives lisdexamfetamine a lower abuse potential relative to immediate-release amphetamine. A human abuse-liability study by Jasinski and Krishnan (2009) found that intranasal lisdexamfetamine produced significantly lower "drug liking" scores compared with equivalent doses of immediate-release d-amphetamine 6. This pharmacologic property matters clinically but does not always translate into formulary preference, because insurers weigh cost-effectiveness alongside safety profiles.

Generic lisdexamfetamine, now manufactured by multiple companies including Teva and Alvogen, typically costs $30 to $80 per month with insurance and $150 to $250 without. If SelectHealth's formulary includes generic lisdexamfetamine at a lower tier, patients may be able to access the same active molecule at substantially reduced cost.

What to Do If SelectHealth Denies Coverage

A coverage denial does not have to be the final answer. Multiple pathways exist for obtaining Vyvanse or generic lisdexamfetamine even after an initial rejection.

File an appeal. SelectHealth's internal appeals process allows members to challenge a denial within 180 days. Include a letter of medical necessity from the prescribing physician, documentation of prior medication trials, relevant clinical notes, and any supporting evidence such as neuropsychological testing results. Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "When prior authorization is denied for lisdexamfetamine, a well-documented appeal that details the patient's treatment history and the clinical rationale for this specific agent is successful in the majority of cases" 7.

Request a formulary exception. If Vyvanse is not on the formulary at all, a formulary exception request asks SelectHealth to cover it as a one-time or ongoing exception. The prescriber must demonstrate that formulary alternatives are medically inappropriate for the specific patient. Criteria that strengthen an exception request include documented adverse reactions to formulary stimulants, comorbid substance use disorder (where lisdexamfetamine's lower abuse potential is clinically relevant), or a diagnosis of binge eating disorder, for which lisdexamfetamine is the only FDA-approved stimulant medication 8.

Use manufacturer or pharmacy savings programs. Takeda's Vyvanse savings program has historically offered eligible commercially insured patients a copay as low as $30 per month. Eligibility excludes government-insured patients (Medicare, Medicaid, Tricare). For generic lisdexamfetamine, GoodRx and similar discount platforms may offer prices below the insurance copay at certain pharmacies, and patients should compare their copay to cash-price alternatives.

Switch to the generic. If the prescriber and patient are comfortable with generic lisdexamfetamine, requesting the generic version often resolves coverage issues entirely. SelectHealth's pharmacy benefit manager may cover generic lisdexamfetamine at Tier 1 or Tier 2, reducing out-of-pocket cost to $10 to $30 per fill.

Vyvanse Coverage for ADHD vs. Binge Eating Disorder

SelectHealth's prior authorization criteria differ depending on the indication. For ADHD, the insurer follows standard step-therapy protocols centered on generic stimulant trials. For binge eating disorder (BED), the pathway is distinct because lisdexamfetamine is the only FDA-approved medication for this condition.

The FDA approved Vyvanse for moderate-to-severe BED in adults in January 2015, based on two key Phase 3 trials. In Study 1 (N=383) and Study 2 (N=390), lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week compared with placebo. At 12 weeks, the 70 mg dose reduced weekly binge days from a baseline of approximately 4.5 to 1.1, compared with a reduction to 2.5 for placebo (P<0.001) 9.

When Vyvanse is prescribed for BED, SelectHealth may not require prior stimulant trials because no generic stimulant holds an FDA indication for this disorder. The prior authorization criteria for BED typically focus on confirming the diagnosis meets DSM-5 criteria (recurrent binge eating episodes at least once per week for three months), ruling out purging behaviors (which would indicate bulimia nervosa instead), and verifying that the patient is not using Vyvanse for weight loss, an explicitly non-approved use.

Dr. Susan McElroy, a professor of psychiatry at the University of Cincinnati and lead investigator on the BED trials, has stated: "Lisdexamfetamine addresses a genuine unmet need in binge eating disorder, where patients previously had no approved pharmacotherapy and relied on off-label options with limited evidence" 10.

Patients with comorbid ADHD and BED may find that the BED indication provides a stronger basis for a prior authorization request, especially if generic stimulant trials for ADHD alone were partially effective but did not address binge eating symptoms.

SelectHealth Medicare Advantage and Medicaid Considerations

Coverage rules differ significantly between SelectHealth's commercial, Medicare Advantage, and Medicaid managed-care products.

Medicare Advantage (SelectHealth Advantage). Medicare Part D formularies are regulated by the Centers for Medicare & Medicaid Services (CMS), which requires that plans cover at least two drugs in each therapeutic class. Because multiple generic stimulants exist in the ADHD class, SelectHealth Advantage is not required to cover brand Vyvanse. Generic lisdexamfetamine is more likely to appear on the Medicare formulary. CMS data from 2024 showed that the average Medicare Part D out-of-pocket cost for brand Vyvanse before reaching the catastrophic coverage phase was $180 to $350 per month, compared with $15 to $45 for generic lisdexamfetamine 11.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully effective as of 2025, can help Medicare beneficiaries who take Vyvanse alongside other brand-name medications. Once a patient's true out-of-pocket spending (excluding premiums) reaches $2 to 000 in a calendar year, they pay nothing further for covered Part D drugs.

Medicaid managed care. SelectHealth administers Medicaid managed-care plans in Utah. State Medicaid formularies generally include generic lisdexamfetamine but may restrict brand Vyvanse more tightly than commercial plans. Utah Medicaid requires prior authorization for all brand-name medications when a generic equivalent exists, and prescribers must document medical necessity for the brand. The Medicaid Drug Rebate Program ensures that manufacturers provide rebates that lower the net cost to state programs, but these savings are not passed directly to patients at the pharmacy counter.

Comparing Lisdexamfetamine to Other Covered ADHD Medications

Understanding where lisdexamfetamine fits among SelectHealth's formulary alternatives helps patients and prescribers make informed decisions.

Generic methylphenidate extended-release is typically the lowest-cost option on SelectHealth formularies. A Cochrane systematic review of 38 trials (N=5,111) found that methylphenidate reduced ADHD symptoms by a standardized mean difference of -0.55 (95% CI: -0.69 to -0.40) versus placebo in children and adolescents, indicating moderate-to-large effect sizes 12. Duration of action ranges from 8 to 12 hours depending on the formulation.

Generic mixed amphetamine salts (extended-release) offer another first-line option at Tier 1 or Tier 2 pricing. The CADDRA (Canadian ADHD Resource Alliance) guidelines note that amphetamine-based and methylphenidate-based stimulants have comparable overall efficacy, with individual patient response varying unpredictably between the two classes.

Atomoxetine (generic Strattera), a non-stimulant, is typically covered on Tier 2 and does not require a controlled-substance prescription. It is preferred for patients with comorbid anxiety or substance use disorder but has a slower onset of action (4 to 6 weeks for full effect) and a smaller average effect size compared with stimulants.

Guanfacine extended-release (generic Intuniv) occupies the non-stimulant Tier 2 space as well, FDA-approved for ADHD in children and adolescents aged 6 to 17. It is often used as adjunctive therapy alongside stimulants rather than as monotherapy.

Lisdexamfetamine's clinical advantages over these alternatives include its longer duration (10 to 14 hours), reduced abuse potential due to the prodrug mechanism, and its unique BED indication. These factors may justify a higher-tier copay for patients who genuinely need them, but they must be documented for SelectHealth to approve coverage over lower-cost options.

How to Check Your Specific SelectHealth Plan

Formulary lookup is straightforward. Visit the SelectHealth member portal online, select "Pharmacy" or "Formulary," and search for "lisdexamfetamine" or "Vyvanse." The results will display the tier, any quantity limits, prior authorization requirements, and step-therapy criteria specific to your plan.

If you do not have online access, call SelectHealth member services at the number printed on the back of your insurance card. Ask specifically: "Is lisdexamfetamine covered on my formulary, at what tier, and what are the prior authorization criteria?" Request a copy of the prior authorization form so your prescriber can submit it proactively before you arrive at the pharmacy.

Patients filling a new Vyvanse prescription should also ask the pharmacy to run a test claim before the appointment ends. A test claim reveals the exact copay or coinsurance amount and flags any prior authorization requirements before the patient leaves empty-handed. If the test claim shows an unexpectedly high cost, ask the pharmacist to check whether generic lisdexamfetamine is available at a lower tier on your specific plan.